Literature DB >> 10509004

Light-chain paraproteins with lupus anticoagulant activity.

Z Yasin1, D Quick, P Thiagarajan, D Spoor, J Caraveo, J Palascak.   

Abstract

A patient with newly diagnosed multiple myeloma manifested by urine kappa light-chain excretion and a small monoclonal spike (0.4 g/dl), presented with lower extremity deep venous thrombosis. A preheparin plasma-activated partial thromboplastin time (aPTT) was prolonged at 68 sec (normal control 26-42 sec). Additional studies confirmed the presence of lupus anticoagulant activity in the serum: the modified Russell Viper Venom Time (MRVVT) was 73 sec (normal control 24-42 sec) and with a 50:50 mix of the patient's plasma and pooled normal plasma, the MRVVT remained prolonged. Kappa light chains (LC) were isolated from the patient's urine and their purity confirmed by electrophoresis and immunofixation using specific immunoglobulin antisera. The patient's LC mixed with pooled normal plasma demonstrated LA activity by in vitro clotting tests (plasma-activated partial thromboplastin time 62 sec, with normal control of 45 sec), MRVVT of 44 sec with normal control of 35 sec. Purified urinary kappa light chains from a control patient with multiple myeloma and normal clotting studies, failed to prolong either the plasma-activated partial thromboplastin time or the MRVVT. We hypothesize that kappa LC in our patient demonstrated LA activity, which was unique to these LCs. Paraproteins with LA activity, to date, have included only intact immunoglobulins (Ig). While intact Ig paraproteins have been reported to possess LA activity, this is the first report to our knowledge of light-chain paraproteins possessing similar activity and resulting in clinically evident thrombosis. Light chain paraproteins could serve as useful models for further study of the mechanisms of activity of acquired LA inhibitors. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509004     DOI: 10.1002/(sici)1096-8652(199910)62:2<99::aid-ajh6>3.0.co;2-n

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

1.  Multiple myeloma presenting as mesenteric venous thrombosis and intestinal infarction.

Authors:  Darren A Kastin; John Andrews; Rohit Shah; David Green; John Fryer; Alan L Buchman
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

2.  Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.

Authors:  A Shinagawa; H Kojima; T Kobayashi; K Kawada; T Nagasawa
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

Review 3.  Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.

Authors:  Yonal Ipek; Hindilerden Fehmi; Besisik-Kalayoglu Sevgi; Sargin Deniz
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

4.  Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors.

Authors:  Noha Abdel-Wahab; Jean H Tayar; Faisal Fa'ak; Gaurav Sharma; Maria A Lopez-Olivo; Abdelrahman Yousif; Tasneam Shagroni; Sami Al-Hawamdeh; Cristhiam M Rojas-Hernandez; Maria E Suarez-Almazor
Journal:  Blood Adv       Date:  2020-04-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.